U.S., Aug. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07738939) titled 'IKS04 Regimen in Advanced Solid Tumors That Express CA242' on July 23.
Brief Summary: This study will evaluate the safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of the IKS04 Regimen and identify a recommended phase 2 dose (RP2D) or recommended dose for further evaluation in expansion (RDE). The regimen includes Isumab04 (unconjugated antibody) followed by the IKS04 antibody-drug conjugate, both directed against the CA242 (CanAg) tumor-associated antigen and administered intravenously (IV) in patients with advanced solid cancers.
Study Start Date: Nov., 2026
Study Type: INTERVENTION...